Follow
Jill A. Fisher
Title
Cited by
Cited by
Year
Benefits of ‘observer effects’: lessons from the field
T Monahan, JA Fisher
Qualitative Research 10 (3), 357-376, 2010
4602010
Medical research for hire: the political economy of pharmaceutical clinical trials
JA Fisher
Rutgers University Press, 2009
3462009
Tattooing the body, marking culture
JA Fisher
Body & society 8 (4), 91-107, 2002
3182002
Tracking the social dimensions of RFID systems in hospitals
JA Fisher, T Monahan
International journal of medical informatics 77 (3), 176-183, 2008
3142008
Challenging Assumptions About Minority Participation in US Clinical Research
JA Fisher, CA Kalbaugh
American journal of public health 101 (12), 2217-2222, 2011
3122011
Treatment of overactive bladder in women
KE Hartmann, ML McPheeters, DH Biller, RM Ward, JN McKoy, ...
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2009
1812009
Strategies for Obtaining Access to Secretive or Guarded Organizations
T Monahan, JA Fisher
Journal of Contemporary Ethnography 44 (6), 709-736, 2015
1442015
Expanding the Frame of "Voluntariness" in Informed Consent: Structural Coercion and the Power of Social and Economic Context
JA Fisher
Kennedy Institute of Ethics Journal 23 (4), 355-379, 2013
1222013
Evaluation of real-time location systems in their hospital contexts
JA Fisher, T Monahan
International Journal of Medical Informatics 81 (10), 705-712, 2012
1172012
Co‐ordinating ‘ethical’ clinical trials: the role of research coordinators in the contract research industry
JA Fisher
Sociology of health & illness 28 (6), 678-694, 2006
892006
“Ready-to-recruit” or “ready-to-consent” populations? Informed consent and the limits of subject autonomy
JA Fisher
Qualitative Inquiry 13 (6), 875-894, 2007
762007
Coming soon to a physician near you: Medical neoliberalism and pharmaceutical clinical trials
JA Fisher
Harvard health policy review 8 (1), 61, 2007
762007
Indoor positioning and digital management: Emerging surveillance regimes in hospitals
JA Fisher
Surveillance and security: Technological politics and power in everyday life …, 2006
712006
Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment
GE Henderson, HL Peay, E Kroon, RJ Cadigan, K Meagher, T Jupimai, ...
Journal of medical ethics 44 (4), 270-276, 2018
632018
Peering into the pharmaceutical “pipeline”: investigational drugs, clinical trials, and industry priorities
JA Fisher, MD Cottingham, CA Kalbaugh
Social Science & Medicine 131, 322-330, 2015
612015
Procedural misconceptions and informed consent: insights from empirical research on the clinical trials industry
JA Fisher
Kennedy Institute of Ethics Journal 16 (3), 251-268, 2006
592006
Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals
JA Fisher
New York University Press, 2020
562020
Feeding and bleeding: The institutional banalization of risk to healthy volunteers in phase I pharmaceutical clinical trials
JA Fisher
Science, Technology, & Human Values 40 (2), 199-226, 2015
542015
‘I'm still a hustler’: entrepreneurial responses to precarity by participants in phase I clinical trials
T Monahan, JA Fisher
Economy and Society 44 (4), 545-566, 2015
512015
Sex, gender, and pharmaceutical politics: from drug development to marketing
JA Fisher, LM Ronald
Gender medicine 7 (4), 357-370, 2010
512010
The system can't perform the operation now. Try again later.
Articles 1–20